⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8909574 | 0.84 | — | — | |
| SCHEMBL161626 | 0.75 | — | — | |
| Ammonia Solution, Strong SCHEMBL355105 | 0.72 | — | — | |
| SCHEMBL8050146 | 0.72 | — | — | |
| Hydrogen Sulfide SCHEMBL5678801 | 0.72 | — | — | |
| SCHEMBL258284 | 0.69 | — | — | |
| SCHEMBL960157 | 0.69 | — | — | |
| SCHEMBL10473433 | 0.69 | TSHR (0.36) | — | |
| SCHEMBL28227326 | 0.69 | — | — | |
| SCHEMBL2648273 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113121609-B | Metal complex, electroluminescent device comprising same and application of metal complex | 北京夏禾科技有限公司 | 2024-03-29 | — | — | CN | claimed |
| US-11352321-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | claimed |
| US-20220131093-A1 | METAL COMPLEX, ELECTROLUMINESCENT DEVICE INCLUDING THE SAME, AND USE THEREOF | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2022-04-28 | — | — | US | claimed |
| CN-113735911-A | Metal complex, electroluminescent device and application thereof | 北京夏禾科技有限公司 | 2021-12-03 | — | — | CN | claimed |
| CN-113121609-A | Metal complex, electroluminescent device comprising metal complex and application of electroluminescent device | 北京夏禾科技有限公司 | 2021-07-16 | — | — | CN | claimed |
| US-20190330144-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-10-31 | — | — | US | claimed |
| US-10221130-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | claimed |
| EP-3153501-B1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS INC (US) | 2018-11-28 | — | — | EP | claimed |
| US-10076504-B2 | Glucagon antagonists | LIGAND PHARMACEUTICALS, INC. | 2018-09-18 | — | — | US | claimed |
| US-20180022695-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2018-01-25 | — | — | US | claimed |
| JP-2012500212-A | — | — | 2012-01-05 | — | — | JP | claimed |
| EP-2326618-A1 | GLUCAGON ANTAGONISTS | Metabasis Therapeutics, Inc. (US) | 2011-06-01 | — | — | EP | claimed |
| WO-2010019830-A1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | WO | claimed |
| US-20090156589-A1 | 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-18 | — | — | US | claimed |
| US-7410971-B2 | 1,2-di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-08-12 | — | — | US | claimed |
| EP-1892238-A1 | 1, 2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2008-02-27 | — | — | EP | claimed |
| US-20060281747-A1 | 1,2-di(cyclic) substituted benzene derivatives | EISAI R&D MANAGEMENT CO., LTD. | 2006-12-14 | — | — | US | claimed |
| US-20060276465-A1 | 1,2-di(cyclic) substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-12-07 | — | — | US | claimed |
| EP-1698620-A1 | BENZENE COMPOUNDS DISUBSTITUTED WITH CYCLIC GROUPS AT THE 1- AND 2-POSITIONS | Eisai Co., Ltd. (JP) | 2006-09-06 | — | — | EP | claimed |
| US-20050261291-A1 | 1,2-Di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | claimed |